Jack A. Khattar - Sep 7, 2023 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: President, CEO, Director
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Stock symbol: SUPN
Transactions as of: Sep 7, 2023
Transactions value $: -$539,408
Form type: 4
Date filed: 9/7/2023, 05:00 PM
Previous filing: Aug 25, 2023
Next filing: Dec 18, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SUPN	Common Stock	Options Exercise	$0	+35K	+4.12%	$0.00	884K	Sep 7, 2023	Direct	F1
transaction	SUPN	Common Stock	Tax liability	-$539K	-16.8K	-1.9%	$32.10	867K	Sep 7, 2023	Direct	F2
holding	SUPN	Common Stock						1.04M	Sep 7, 2023	By the KBT Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Performance Share Unit	Options Exercise	$0	-35K	-100%	$0.00^*	0	Sep 7, 2023	Common Stock	35K	$0.00	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 23, 2023.
F2	Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the PSU vesting.
F3	On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.